Behavioral Health Integration for Medicare Members

FDA Approved 55 New Treatments in 2023

In 2023, the U.S. Food and Drug Administration (FDA) increased their approvals by 50% since 2022, approving 55 new treatments. On average, the FDA typically approves 45-50 drugs every year. The number of approved drugs depends upon the complexity of newly developed drugs and the advancements in the understanding of diseases.

In 2023, the FDA notably approved obesity drugs Zepbound and Eisai, Alzheimer’s treatment Leqembi, and gene therapies, including a sickle cell disease treatment. Of these approvals, Pfizer obtained 7 high-profile approvals, twice as many as any other company.

As FDA drug approvals seem to be returning to pre-pandemic levels, experts expect another robust year in 2024. Moving forward, employers who are providing health benefits may want to consider including the newly approved drugs in their formularies or adjusting existing coverage policies.

 

As more information is made available, Creative Benefits, Inc. will provide additional updates.